Short Interest in Theratechnologies Inc. (NASDAQ:THTX) Expands By 31.4%

Theratechnologies Inc. (NASDAQ:THTX - Get Free Report) was the recipient of a large growth in short interest during the month of August. As of August 15th, there was short interest totaling 300,200 shares, agrowthof31.4% from the July 31st total of 228,400 shares. Based on an average daily volume of 484,300 shares, the days-to-cover ratio is currently 0.6 days. Currently,0.8% of the shares of the stock are short sold. Currently,0.8% of the shares of the stock are short sold. Based on an average daily volume of 484,300 shares, the days-to-cover ratio is currently 0.6 days.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Raymond James Financial Inc. acquired a new position in shares of Theratechnologies during the 4th quarter valued at about $27,000. BNP Paribas Financial Markets acquired a new position in shares of Theratechnologies during the 4th quarter valued at about $36,000. National Bank of Canada FI increased its stake in shares of Theratechnologies by 2.6% during the 1st quarter. National Bank of Canada FI now owns 197,068 shares of the company's stock valued at $282,000 after acquiring an additional 4,938 shares during the last quarter. Stonepine Capital Management LLC acquired a new position in shares of Theratechnologies during the 1st quarter valued at about $36,000. Finally, Cyndeo Wealth Partners LLC acquired a new position in shares of Theratechnologies during the 1st quarter valued at about $42,000.

Wall Street Analyst Weigh In

Separately, Jones Trading downgraded shares of Theratechnologies from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 3rd. One analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy".

Theratechnologies Price Performance

NASDAQ THTX opened at $3.27 on Tuesday. Theratechnologies has a 12 month low of $1.12 and a 12 month high of $3.28. The company has a 50-day moving average of $3.16 and a 200-day moving average of $2.53. The company has a market cap of $150.35 million, a P/E ratio of -17.21 and a beta of 0.51.

Theratechnologies (NASDAQ:THTX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 9th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.08). The firm had revenue of $17.73 million for the quarter, compared to the consensus estimate of $24.30 million. As a group, equities research analysts anticipate that Theratechnologies will post 0.01 EPS for the current year.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.